The peptide stack your clinic prescribed came without a dosing protocol

Walk out of an anti-aging clinic today and you can leave with three peptide vials stacked on top of the GLP-1 you already take. Retatrutide to keep the fat loss going, a growth-hormone secretagogue pair like CJC-1295 and ipamorelin to protect muscle. What you often do not leave with is the one thing that makes a stack safe: a dosing protocol. The prescription is real. The titration schedule, the cycling, the how-much-and-when is left to you.

That is the gap. Not the access, not the price. The protocol.

The stack is specific, and clinicians prescribe it

This is not fringe. The lean-recomp protocols circulating in peptide clinics are named and repeatable. One is retatrutide plus tesamorelin. Another is retatrutide plus CJC-1295 plus ipamorelin, both growth-hormone secretagogues, run alongside continuous reta. Foundation work (protein, resistance training) is treated as non-negotiable underneath.

Retatrutide itself is still investigational: it sits in trials, not on an approved label, and every microdosing pattern built around it is off-label. That matters here. The further a compound sits from an approved label, the more the dosing schedule depends on a clinician who is actually watching, and the less there is a package insert to fall back on.

The missing part is the part that matters

A stack is not a list of vials. It is a schedule. And the schedule is where clinic prescriptions tend to go quiet. Three things routinely get left out:

• Titration. "Start low, go slow" is repeated everywhere and formalized almost nowhere. Finding a minimum effective dose is still, in the community's own words, undocumented art. The same missing-number problem shows up compound by compound: ipamorelin's minimum effective dose was never actually written down.
• Buildup. Retatrutide has roughly a 6-day half-life, so the drug keeps accumulating for 3 to 4 weeks before it levels off. Someone who does not know that reads a quiet first week as "not working" and pushes the dose too early. Starting two GLP-1s at once is the same mistake in a different shape.
• Cycling. The growth-hormone secretagogue half of these stacks needs cycling because the receptors downregulate without a break. For the CJC-1295 plus ipamorelin pairing, the cycling guidance in the clinical framework is literally marked TBD, unresolved even among the clinicians who prescribe it.

If the people writing the prescription have not pinned the cycling, the patient dosing at home has not either.

Even the clinicians disagree

Dig into the framework and the disagreement is on the record. One MD runs the retatrutide-plus-secretagogue stack as routine and argues it flips the muscle-preservation math. Another argues the growth-hormone agonists may not be necessary at all. Both prescribe. They do not agree on whether half the stack should exist.

There is even confusion about what a starting dose is. Reta at 1 to 2 mg per week reads like a microdose to a lot of people. One clinician's flat correction: that is the clinical-trial starting dose, not a microdose, and a true microdose is closer to 0.25 to 0.5 mg. Read those two numbers as the same thing on your own and you are off by up to 8x, in the direction of more drug. Retatrutide is not the only compound where the maintenance math is undefined: reta's own maintenance phase has no protocol either.

This is not hypothetical

The consequences show up at the prescribing step, not just in DIY. One telehealth compounding clinic was reported prescribing 9 mg tirzepatide as a first-ever dose to a patient whose only prior GLP-1 exposure was a low-dose oral for one month. That is a clinic, not a Telegram seller.

And the supervision gap now has mainstream cover. When reporters put the question to bariatric and cardiology specialists, the read was blunt: losing this much weight this fast needs close medical management, much more than most people get on a standard GLP-1 script. Bone density and muscle mass were the named risks. The stack is supposed to answer the muscle half. Nobody is answering the dosing half.

Why the gap exists

Follow the money and the gap makes sense. In compounding, the vial is the billable unit. A pharmacy charges the clinician around $150 a vial; the patient is billed somewhere between $200 and $800. The spread is the business. The protocol, the hour of titration planning and the monthly check-ins, is unbillable work that eats the margin. So the incentive is to ship the vial and let the dosing plan sort itself out.

What to actually do

You cannot fix a clinic's incentives. You can refuse to leave without the protocol.

• Ask your clinician to put the full schedule in writing: start dose, titration steps, the interval between each increase, and the cycling plan for any growth-hormone secretagogue. A stack without a written schedule is half a prescription.
• Know the difference between a trial starting dose and a microdose before you touch the vial, and confirm which one your clinician actually intends.
• Get the vial's purity tested. You cannot dose what you cannot quantify: at unknown concentration, dosing errors of roughly 5x are common, since the powder can be mostly unidentified filler. Here is how to vet a supplier and read a COA.

The stack your clinic prescribed can be the right call. A stack without a dosing protocol is not a plan. It is an open question you are answering alone. We track these dosing gaps compound by compound on the Ouros Lab feed. Ask your clinician for the rest of it.